Clayton Russell 4

What Happened

• Clayton Russell, Chief Medical Officer of Larimar Therapeutics (LRMR), received equity awards on 2026-01-26 consisting of 25,637 RSUs and 153,822 RSU-type derivative awards (total 179,459 units). Each unit was granted at $0.00 (no cash paid at grant); this is an award/grant (transaction code A), not a purchase or sale.

Key Details

• Transaction date: 2026-01-26; Form 4 filed 2026-01-27 (timely).
• Grant amounts and prices: 25,637 RSUs @ $0.00; 153,822 derivative RSU units @ $0.00.
• Shares owned after transaction: Not disclosed in the filing.
• Footnotes: F1 — each unit is a restricted stock unit (RSU) that converts to one share upon settlement; F2 — vesting schedule: 25% vests on Jan 26, 2027, then the remaining 75% vests in equal monthly installments over the next 36 months, subject to continued service.
• Transaction type: Award/Grant (A). No sale, exercise, or cashless transaction reported.

Context

• RSUs are deferred compensation: they give a contingent right to receive shares later and generally reflect executive compensation rather than an immediate market bet. Vesting conditions mean the shares will be delivered over time if the executive remains with the company.